Landfar(SZ:000504)2019-04-29 16:00Financial Performance - The company's revenue for Q1 2019 was ¥29,775,813.30, representing a 74.16% increase compared to ¥17,096,871.95 in the same period last year[8]. - The net profit attributable to shareholders was a loss of ¥6,546,948.14, an improvement of 9.89% from a loss of ¥7,265,661.50 in the previous year[8]. - The company's operating revenue increased by 74.16% to CNY 29,775,813.30 compared to CNY 17,096,871.95 in the previous period, driven by growth in stem cell storage and antibody business[15]. - The company reported a net loss of CNY 13,976,676.64 for Q1 2019, compared to a net loss of CNY 8,657,009.42 in the previous year[39]. - The comprehensive income totalled a loss of CNY 6,777,772.19, compared to a loss of CNY 6,364,539.58 in the prior period[43]. Cash Flow - The net cash flow from operating activities improved by 38.07%, with a net outflow of ¥8,628,981.65 compared to ¥13,934,062.63 in the same period last year[8]. - The company's cash flow from operating activities showed a significant increase, with cash received from operating activities rising by 68.51% to CNY 12,298,192.94[15]. - The cash flow from operating activities was CNY 30,536,901.97, showing an increase from CNY 21,338,542.81 in the previous period[49]. - The net cash flow from investing activities was -676,078.44 yuan, compared to -32,519,156.54 yuan previously, showing a substantial decrease in cash outflow[51]. - The company reported a net increase in cash and cash equivalents of 14,383,184.16 yuan, contrasting with a decrease of 48,869,433.73 yuan in the last period[51]. Assets and Liabilities - The total assets at the end of the reporting period were ¥360,972,527.49, a 5.33% increase from ¥342,705,746.30 at the end of the previous year[8]. - The company's total liabilities rose to CNY 259,999,281.69 from CNY 234,954,728.31, an increase of approximately 10.7%[34]. - The company's short-term borrowings increased significantly to CNY 140,000,000.00 from CNY 70,000,000.00, marking a 100% increase[37]. - The total current assets were CNY 59,004,735.29, with cash and cash equivalents at CNY 32,789,220.92[60]. - The total owner's equity was CNY 107,751,017.99, with minority interests at CNY 118,001,409.20[59]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 14,139[11]. - The largest shareholder, Hunan Trust Co., Ltd., held 25.58% of the shares, amounting to 79,701,655 shares[11]. - The company did not engage in any repurchase transactions during the reporting period[12]. Expenses - Research and development expenses rose by 108.88% to CNY 3,294,099.47, reflecting increased investment in antibody business[15]. - Sales expenses surged by 132.03% to CNY 7,091,789.60, correlating with the increase in revenue from stem cell storage services[15]. - Total operating costs for Q1 2019 were CNY 36,482,290.79, up from CNY 22,596,686.86, indicating a rise of about 61.3%[40]. - The financial expenses for the quarter amounted to CNY 3,132,019.91, an increase from CNY 2,695,049.10 in the previous year[45]. Compliance and Governance - The company has committed to ensuring that related party transactions do not harm the interests of shareholders, maintaining compliance with legal procedures[21]. - There were no reported violations regarding external guarantees or non-operational fund occupation by controlling shareholders during the reporting period[26][27]. - The company has not engaged in derivative investments during the reporting period, indicating a conservative approach to financial risk management[24]. - The company has not undergone an audit for the first quarter report[62].